These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 3085632

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers.
    Siegbahn A, Ruusuvaara L.
    Thromb Haemost; 1988 Dec 22; 60(3):361-4. PubMed ID: 3149043
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Vascular and fibrinolytic effects of intra-arterial tumour necrosis factor-alpha in patients with coronary heart disease.
    Robinson SD, Dawson P, Ludlam CA, Boon NA, Newby DE.
    Clin Sci (Lond); 2006 Mar 22; 110(3):353-60. PubMed ID: 16309383
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Fibrinolysis in normal subjects--comparison between plasminogen activator inhibitor and other components of the fibrinolytic system.
    Nicoloso G, Hauert J, Kruithof EK, Van Melle G, Bachmann F.
    Thromb Haemost; 1988 Apr 08; 59(2):299-303. PubMed ID: 3133812
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Endothelial cell activation in cutaneous vasculitis.
    Jurd KM, Stephens CJ, Black MM, Hunt BJ.
    Clin Exp Dermatol; 1996 Jan 08; 21(1):28-32. PubMed ID: 8689765
    [Abstract] [Full Text] [Related]

  • 15. Fibrinolysis abnormalities in systemic lupus erythematosus and their relation to vasculitis.
    Awada H, Barlowatz-Meimon G, Dougados M, Maisonneuve P, Sultan Y, Amor B.
    J Lab Clin Med; 1988 Feb 08; 111(2):229-36. PubMed ID: 3123585
    [Abstract] [Full Text] [Related]

  • 16. Reproducibility of fibrinolytic response to venous occlusion in healthy subjects.
    Stegnar M, Mavri A.
    Thromb Haemost; 1995 Mar 08; 73(3):453-7. PubMed ID: 7667828
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
    Munkvad S.
    Dan Med Bull; 1993 Sep 08; 40(4):383-408. PubMed ID: 8222763
    [Abstract] [Full Text] [Related]

  • 19. Fibrinolytic activity during hemodialysis: a biocompatibility-related phenomenon.
    Martin-Malo A, Velasco F, Rojas R, Castillo D, Rodriguez M, Torres A, Aljama P.
    Kidney Int Suppl; 1993 Jun 08; 41():S213-6. PubMed ID: 8320924
    [Abstract] [Full Text] [Related]

  • 20. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
    Rość D, Kremplewska-Nalezyta E, Gadomska G, Zastawna E, Michalski A, Drewniak W.
    Med Sci Monit; 2000 Jun 08; 6(4):684-91. PubMed ID: 11208392
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.